Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ocular Therapeutix, Inc. filings document the formal disclosure record for a Nasdaq-listed biopharmaceutical issuer developing and commercializing ophthalmic therapies. Form 8-K reports furnish operating and financial results, Regulation FD materials and clinical-trial disclosures tied to AXPAXLI in wet age-related macular degeneration, along with material-event reporting on governance matters, executive officer arrangements, material agreements and capital-structure disclosures.
Proxy materials cover shareholder voting matters, executive compensation and equity-award disclosures, including information presented under pay-versus-performance reporting. The filings also identify Ocular Therapeutix common stock, par value $0.0001 per share, as registered on The Nasdaq Global Market under the symbol OCUL.
On 06/11/2025, Ocular Therapeutix (OCUL) Chief Commercial Officer Steve Lawrence Meyers filed a Form 3, establishing his initial beneficial ownership. He directly owns 152,728 common shares, including 117,317 unvested RSUs granted in 2023-2025 under the company’s 2021 Stock Incentive Plan. In addition, Meyers holds four option grants totaling 512,000 shares with strike prices ranging from $3.88 to $7.44 and expirations between 2032-2035; each option vests monthly over four years. The filing is routine, reflects no open-market purchases or sales, and does not alter the company’s capital structure.
Ocular Therapeutix (OCUL) filed a Form 3 disclosing the initial beneficial ownership of its newly appointed Chief Business Officer, Namrata Saroj. The filing reports direct ownership of 200,000 unvested restricted stock units (RSUs) that will vest in three equal annual installments beginning on the first anniversary of her start date.
Derivative holdings include 466,000 stock options spread across three grants: 50,000 options already fully vested at an exercise price of $9.95 expiring 02/27/2034; 100,000 options granted 02/28/2024 at $9.95 vesting 1/48 monthly after an initial one-year cliff; and 316,000 options granted 11/04/2024 at $10.27 with similar four-year vesting. All holdings are reported as direct ownership.
The filing is routine, conveys no operational or financial performance data, and does not imply the insider owns more than 10 % of outstanding shares.